{"entity":{"id":"nct00553306","kind":"trial","name":"CD8+ antigen-specific T-cell clones after cyclophosphamide, with aldesleukin, in stage IV melanoma (Fred Hutchinson phase 1/2, NCI-2010-01281)","aka":[],"tldr":"A Seattle trial in 10 people with advanced melanoma testing the side effects and effect of their own laboratory-grown T cells given after cyclophosphamide, with IL-2. It ran from 2007 to 2012.","summary":"The registry describes a phase I/II study of autologous CD8+ antigen-specific T-cell clones following cyclophosphamide conditioning, with aldesleukin, in metastatic melanoma, started in September 2007, with primary completion in August 2010, completion in March 2012 and an actual enrolment of 10 (ClinicalTrials.gov NCT00553306). Cassian Yee is listed as principal investigator and Fred Hutchinson Cancer Center as sponsor (ClinicalTrials.gov NCT00553306). No results are posted.","status":"completed","asOf":"2026-11-05","links":[{"label":"ClinicalTrials.gov NCT00553306","url":"https://clinicaltrials.gov/study/NCT00553306"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","aldesleukin"],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"nct":"NCT00553306","phase":"1/2","setting":"Stage IV or recurrent melanoma: cyclophosphamide, then laboratory-expanded autologous CD8+ antigen-specific T cells and aldesleukin","sponsor":"Fred Hutchinson Cancer Center","result":"No results posted on ClinicalTrials.gov.","started":"2007-09","startedType":"actual","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00553306/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}